C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 85 filers reported holding C4 THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,630 | -39.9% | 14,855 | -11.2% | 0.00% | – |
| Q2 2023 | $46,008 | -4.5% | 16,730 | +9.0% | 0.00% | – |
| Q1 2023 | $48,174 | -62.9% | 15,342 | +3.5% | 0.00% | -100.0% |
| Q3 2022 | $130,000 | +16.1% | 14,822 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $112,000 | -68.9% | 14,822 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $360,000 | -43.4% | 14,822 | -25.0% | 0.00% | -50.0% |
| Q4 2021 | $636,000 | -46.0% | 19,762 | -25.0% | 0.00% | -60.0% |
| Q3 2021 | $1,177,000 | +18.1% | 26,349 | 0.0% | 0.01% | +11.1% |
| Q2 2021 | $997,000 | +24825.0% | 26,349 | +24297.2% | 0.01% | – |
| Q1 2021 | $4,000 | – | 108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |